1. Home
  2. MIST
  3. MIST News

Latest Milestone Pharmaceuticals Inc. (MIST) News on November 27, 2025

Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects
MIST

Insider Monkey

2 days ago

Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate
MIST

Simply Wall St.

10 days ago

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
MIST

GlobeNewswire

15 days ago

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIST

GlobeNewswire

23 days ago

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
MIST

GlobeNewswire

24 days ago

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
MIST

GlobeNewswire

2 months ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

MIST

MT Newswires

5 months ago

Milestone Pharmaceuticals Files Response to FDA for Cardamyst Nasal Spray

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
MIST

GlobeNewswire

5 months ago

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
MIST

GlobeNewswire

6 months ago

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
MIST

Zacks

6 months ago

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

MIST

Associated Press Finance

6 months ago

Milestone Pharmaceuticals: Q1 Earnings Snapshot

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
MIST

GlobeNewswire

6 months ago

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

MIST Stock Falls 66% Following Complete Response Letter for Cardamyst
MIST

Zacks

8 months ago

MIST Stock Falls 66% Following Complete Response Letter for Cardamyst

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen
MIST

TipRanks

8 months ago

Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen

MIST

Investing.com

8 months ago

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty

MIST

MT Newswires

8 months ago

HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating

MIST

MT Newswires

8 months ago

TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright
MIST

TipRanks

8 months ago

Milestone CRL affirms integrity of clinical data, says H.C. Wainwright

MIST

MT Newswires

8 months ago

Top Midday Decliners

MIST

MT Newswires

8 months ago

Sector Update: Health Care Stocks Mixed Friday Afternoon

MIST

MT Newswires

8 months ago

Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating

MIST

MT Newswires

8 months ago

Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall

FDA Issues Complete Response Letter for Etripamil for PSVT
MIST

GlobeNewswire

8 months ago

FDA Issues Complete Response Letter for Etripamil for PSVT

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
MIST

GlobeNewswire

8 months ago

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

MIST

Associated Press Finance

9 months ago

Milestone Pharmaceuticals: Q4 Earnings Snapshot

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
MIST

GlobeNewswire

9 months ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIST

GlobeNewswire

9 months ago

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
MIST

GlobeNewswire

9 months ago

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

MIST

MT Newswires

9 months ago

Milestone Pharmaceuticals Gets Notice of Allowance for US Patent on Etripamil Nasal Spray

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
MIST

GlobeNewswire

9 months ago

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025
MIST

GlobeNewswire

10 months ago

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Loss-Making Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected To Breakeven In The Medium-Term
MIST

Simply Wall St.

10 months ago

Loss-Making Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected To Breakeven In The Medium-Term

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
MIST

GlobeNewswire

10 months ago

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIST

GlobeNewswire

a year ago

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference
MIST

GlobeNewswire

a year ago

Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference

After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright
MIST

Zacks

a year ago

After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright

MIST

Associated Press Finance

a year ago

Milestone Pharmaceuticals: Q3 Earnings Snapshot

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
MIST

GlobeNewswire

a year ago

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46%
MIST

Simply Wall St.

a year ago

Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46%

Milestone Pharmaceuticals to Host Investor KOL Event
MIST

GlobeNewswire

a year ago

Milestone Pharmaceuticals to Host Investor KOL Event

MIST

MT Newswires

a year ago

Milestone Pharmaceuticals' Partner Ji Xing's Phase 3 Trial of Etripamil Meets Primary Endpoint

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
MIST

GlobeNewswire

a year ago

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
MIST

GlobeNewswire

a year ago

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MIST

GlobeNewswire

a year ago

Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024
MIST

GlobeNewswire

a year ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024

MIST

Associated Press Finance

a year ago

Milestone Pharmaceuticals: Q2 Earnings Snapshot

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
MIST

GlobeNewswire

a year ago

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference
MIST

GlobeNewswire

a year ago

Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference

Milestone Pharmaceuticals Refreshes Board of Directors
MIST

GlobeNewswire

a year ago

Milestone Pharmaceuticals Refreshes Board of Directors

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024
MIST

GlobeNewswire

a year ago

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

It Looks Like Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO May Expect Their Salary To Be Put Under The Microscope
MIST

Simply Wall St.

a year ago

It Looks Like Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO May Expect Their Salary To Be Put Under The Microscope

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
MIST

GlobeNewswire

a year ago

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

MIST

MT Newswires

a year ago

Milestone Pharmaceuticals Says US FDA Accepts New Drug Application for Cardamyst Nasal Spray for Arrhythmia

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
MIST

GlobeNewswire

a year ago

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness
MIST

GlobeNewswire

2 years ago

Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know
MIST

Zacks

2 years ago

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know

MIST

Associated Press Finance

2 years ago

Milestone Pharmaceuticals: Q1 Earnings Snapshot

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
MIST

GlobeNewswire

2 years ago

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
MIST

GlobeNewswire

2 years ago

Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
MIST

GlobeNewswire

2 years ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
MIST

GlobeNewswire

2 years ago

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
MIST

GlobeNewswire

2 years ago

Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
MIST

GlobeNewswire

2 years ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
MIST

GlobeNewswire

2 years ago

Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
MIST

GlobeNewswire

2 years ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
MIST

GlobeNewswire

2 years ago

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants
MIST

GlobeNewswire

2 years ago

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
MIST

GlobeNewswire

2 years ago

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT
MIST

GlobeNewswire

2 years ago

Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT

aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
MIST

GlobeNewswire

2 years ago

aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity

Primis Financial Corp. Reports Earnings per Share for the Fourth Quarter of 2023
MIST

PR Newswire

2 years ago

Primis Financial Corp. Reports Earnings per Share for the Fourth Quarter of 2023

HYZON DELIVERS FIRST FOUR FUEL CELL ELECTRIC VEHICLES TO PERFORMANCE FOOD GROUP
MIST

PR Newswire

2 years ago

HYZON DELIVERS FIRST FOUR FUEL CELL ELECTRIC VEHICLES TO PERFORMANCE FOOD GROUP

Here's Why We Think First National (NASDAQ:FXNC) Is Well Worth Watching
MIST

Simply Wall St.

2 years ago

Here's Why We Think First National (NASDAQ:FXNC) Is Well Worth Watching

Arbe Celebrates Milestone Achievements as Sensrad Announces Major Customer Orders for Revolutionary Radar Technology
MIST

GlobeNewswire

2 years ago

Arbe Celebrates Milestone Achievements as Sensrad Announces Major Customer Orders for Revolutionary Radar Technology

Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround
MIST

Zacks

2 years ago

Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround

It Might Not Be A Great Idea To Buy Luxfer Holdings PLC (NYSE:LXFR) For Its Next Dividend
MIST

Simply Wall St.

2 years ago

It Might Not Be A Great Idea To Buy Luxfer Holdings PLC (NYSE:LXFR) For Its Next Dividend

MIST

ACCESSWIRE

2 years ago

Monterey Capital Acquisition Corporation Announces Filing of Registration Statement on Form S-4 in Connection with Its Proposed Business Combination with ConnectM

SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting
MIST

PR Newswire

2 years ago

SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

5 Stocks With Recent Price Strength to Grab Now
MIST

Zacks

2 years ago

5 Stocks With Recent Price Strength to Grab Now

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
MIST

PR Newswire

2 years ago

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update

NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
MIST

News Direct

2 years ago

NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
MIST

Zacks

2 years ago

Milestone Pharma (MIST) Down on Regulatory Update for Etripamil

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
MIST

GlobeNewswire

2 years ago

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) top owners are individual investors with 52% stake, while 34% is held by institutions
MIST

Simply Wall St.

2 years ago

Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) top owners are individual investors with 52% stake, while 34% is held by institutions

Institutional investors may adopt severe steps after Telos Corporation's (NASDAQ:TLS) latest 11% drop adds to a year losses
MIST

Simply Wall St.

2 years ago

Institutional investors may adopt severe steps after Telos Corporation's (NASDAQ:TLS) latest 11% drop adds to a year losses

3 Off-the-Beaten-Path Stocks Poised for Substantial Growth
MIST

InvestorPlace

2 years ago

3 Off-the-Beaten-Path Stocks Poised for Substantial Growth

BEN Appoints Rick Howard as Chief Information and Data Officer
MIST

Business Wire

2 years ago

BEN Appoints Rick Howard as Chief Information and Data Officer

Lifetime Brands' (NASDAQ:LCUT) Dividend Will Be $0.0425
MIST

Simply Wall St.

2 years ago

Lifetime Brands' (NASDAQ:LCUT) Dividend Will Be $0.0425

Cohen & Steers Closed-End Funds Declare Distributions for January, February, and March 2024
MIST

PR Newswire

2 years ago

Cohen & Steers Closed-End Funds Declare Distributions for January, February, and March 2024

Beat the Market the Zacks Way: Shopify, Lululemon, Telos in Focus
MIST

Zacks

2 years ago

Beat the Market the Zacks Way: Shopify, Lululemon, Telos in Focus

Li-Cycle Comments on Process to Evaluate Financing and Strategic Alternatives
MIST

Business Wire

2 years ago

Li-Cycle Comments on Process to Evaluate Financing and Strategic Alternatives

Investors in TETRA Technologies (NYSE:TTI) have seen incredible returns of 440% over the past three years
MIST

Simply Wall St.

2 years ago

Investors in TETRA Technologies (NYSE:TTI) have seen incredible returns of 440% over the past three years

Sidoti Events, LLC's Virtual December Small-Cap Conference
MIST

ACCESSWIRE

2 years ago

Sidoti Events, LLC's Virtual December Small-Cap Conference

Should You Be Worried About Park-Ohio Holdings Corp.'s (NASDAQ:PKOH) 6.8% Return On Equity?
MIST

Simply Wall St.

2 years ago

Should You Be Worried About Park-Ohio Holdings Corp.'s (NASDAQ:PKOH) 6.8% Return On Equity?

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
MIST

Business Wire

2 years ago

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results

MIST

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Duluth Holdings Inc Earnings Call

Duluth (DLTH) Q3 2023 Earnings Call Transcript
MIST

Motley Fool

2 years ago

Duluth (DLTH) Q3 2023 Earnings Call Transcript

Matterport Signs Multi-Year Partnership with Vacasa to Provide Digital Twins for International Portfolio of Vacation Homes
MIST

GlobeNewswire

2 years ago

Matterport Signs Multi-Year Partnership with Vacasa to Provide Digital Twins for International Portfolio of Vacation Homes

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
MIST

Business Wire

2 years ago

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Here's Why We're Watching Immuneering's (NASDAQ:IMRX) Cash Burn Situation
MIST

Simply Wall St.

2 years ago

Here's Why We're Watching Immuneering's (NASDAQ:IMRX) Cash Burn Situation

Share on Social Networks: